Medication info
Lefren Capsule 50 mg (Pregabalin)

Lefren Capsule 50 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
HanKook Pavis Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a blue upper and a white lower part containing white powder
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201902648 · Approved 2019.04.25 · Insurance code 621803610

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at intervals of 7 days up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at intervals of 7 days up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be done gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplementary dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a Starting dose (mg/day) / Maximum dose (mg/day) / Dosing regimen ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12–17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
HanKook Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • secondary general symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used to treat peripheral and central neuropathic pain in adults. It is also administered as an adjunct for partial seizures in patients with epilepsy, whether or not accompanied by secondary general symptoms. Additionally, it helps alleviate symptoms in patients with fibromyalgia. In other words, it is used for neuropathic pain, as an adjunct for partial seizures in epilepsy, and for the treatment of fibromyalgia.

How to take

Adult dose

This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at intervals of 7 days up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at intervals of 7 days up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be done gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplementary dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a Starting dose (mg/day) / Maximum dose (mg/day) / Dosing regimen ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescents aged 12–17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This drug is used for the treatment of epilepsy and may increase the risk of suicidal thoughts or behaviors, so mood changes or behavioral abnormalities should be monitored carefully during use. Patients with hypersensitivity to this drug or genetic lactose-related disorders should not take it. Diabetic patients may need to adjust the dosage of blood sugar-controlling medications due to weight gain, and immediate cessation is required if signs of angioedema occur. Elderly patients may experience an increase in dizziness or drowsiness, leading to a risk of falls, and may experience visual changes such as blurred vision. Abrupt discontinuation of this drug can cause withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be tapered gradually under medical supervision. Due to the potential for drug abuse or dependence, patients with a history of mental illness or drug abuse should be managed carefully. Patients with decreased kidney function may require dosage adjustments, and those with heart disease should use it cautiously. Taking this drug with opioid analgesics may increase central nervous system depressant effects, leading to a risk of respiratory depression. Pregnant women should avoid taking this drug in early pregnancy due to the risk of fetal malformation, and women of childbearing age should use effective contraceptive methods. During breastfeeding, this drug can pass into breast milk and affect the infant, so consideration should be given to stopping breastfeeding or discontinuing the drug. Before driving or operating dangerous machinery, it is important to check for dizziness or drowsiness caused by this drug, and if severe rashes or allergic symptoms appear, immediate cessation of the drug and consultation with a physician should occur. This drug is mainly excreted through the kidneys, so elderly patients or those with decreased kidney function may require dosage adjustments. In cases of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur, and immediate medical treatment should be sought. Keep out of reach of children and do not transfer to other containers for safety.

Side effects

suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, pain, sweating, drug misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, spatial disorientation, irritability, elation, decreased libido, depersonalization, sexual dysesthesia, agitation, mood swings, emotional blunting, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremor, dysarthria, sensory abnormalities, sensory loss, sedation, hypersomnolence, cognitive impairment, nystagmus, aphasia, myoclonus, decreased reflexes, movement disorders, psychomotor agitation, positional vertigo, hyperesthesia, burning sensation, intention tremors, syncope, stupor, hypoactivity, olfactory disturbances, loss of taste, writing difficulties, diplopia, dry eyes, ocular swelling, reduced vision, eye pain, eye fatigue, increased tear production, ocular irritation, mydriasis, cognitive depth perception changes with vibration, strabismus, brightness of vision, vertigo, hyperacusis, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, nasal bleeding, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, joint pain, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urinary disorders, incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, peripheral edema, swelling, gait abnormalities, falls, feeling drunk, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, delirium, paralysis (facial paralysis), affective disorders, drowsiness, state of confusion, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent air or moisture infiltration, preferably in a cool place between 15 and 25 degrees Celsius. Storing it this way will help maintain the drug's efficacy and prevent deterioration.

Appearance and packaging

Appearance

A hard capsule with a blue upper and a white lower part containing white powder

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.